Evidence map›Paper›PMID 38444675›Full record

ArticleFrontiers in oncology2024

Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.

Douglas I Lin, Richard S P Huang, Ioannis Ladas, Rachel B Keller, Nimesh R Patel, Sotirios Lakis, Brennan Decker, Tyler Janovitz, Douglas A Mata, Jeffrey S Ross and 5 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Characterizing Paratesticular Neoplasms in Proteus Syndrome.The American journal of surgical pathology · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Douglas I LinDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Richard S P HuangDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Ioannis LadasDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Rachel B KellerDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Nimesh R PatelDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Sotirios LakisFoundation Medicine GmbH, Pathology Department, Penzberg, Germany.
Brennan DeckerDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Tyler JanovitzDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Douglas A MataDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Jeffrey S RossDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Jo-Anne VergilioDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Julia A ElvinDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.
Roy S HerbstDepartment of Medical Oncology, Yale School of Medicine, Yale Cancer Center, New Haven, CT, United States.
Philip C MackDivision of Hematology and Oncology, Department of Medicine, Tisch Cancer Institute at Mount Sinai, New York, NY, United States.
Jonathan K KillianDepartment of Pathology and Diagnostic Medicine, Foundation Medicine, Inc., Cambridge, MA, United States.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

Background: While many molecular assays can detect mutations at low tumor purity and variant allele frequencies, complex biomarkers such as tumor mutational burden (TMB), microsatellite instability (MSI), and genomic loss of heterozygosity (gLOH) require higher tumor purity for accurate measurement. Scalable, quality-controlled, tissue-conserving methods to increase tumor nuclei percentage (TN%) from tumor specimens are needed for complex biomarkers and hence necessary to maximize patient matching to approved therapies or clinical trial enrollment. We evaluated the clinical utility and performance of precision needle-punch enrichment (NPE) compared with traditional razor blade macroenrichment of tumor specimens on molecular testing success. Methods: Pathologist-directed NPE was performed manually on formalin-fixed, paraffin embedded (FFPE) blocks. Quality control of target capture region and quantity of residual tumor in each tissue block was determined via a post-enrichment histologic slide recut. Resultant tumor purity and biomarker status were determined by the computational analysis pipeline component of the FDA-approved next-generation sequencing (NGS) assay, FoundationOne Results: In real-world clinical samples, enrichment rate via NPE was increased to ~50% over a 2.5-year period, exceeding the prior use of razor blade macro-enrichment (<30% of cases) prior to NPE implementation due to proven efficacy in generating high quality molecular results from marginal samples and the ease of use for both pathologist and histotechnologists. NPE was associated with lower test failures, higher computational tumor purity, and higher rates of successful TMB, MSI and gLOH determination when stratified by pre-enriched (incipient) tumor nuclei percentage. In addition, challenging cases in which tumor content was initially insufficient for testing were salvaged for analysis of biomarker status, gene amplification/deletion, and confident mutant or wild-type gene status determination. Conclusions: Pathologist-directed precision enrichment from tissue blocks (aka NPE) increases tumor purity, and consequently, yields a greater number of successful tests and complex biomarker determinations. Moreover, this process is rapid, safe, inexpensive, scalable, and conserves patient surgical pathology material. NPE may constitute best practice with respect to enriching tumor cells from low-purity specimens for biomarker detection in molecular laboratories.

Indexed as

biomarkerbiomarkersFoundationOne®CDxmolecular diagnosisnext generation sequencingtumor enrichmenttumor microdissectiontumor purity

Identifiers

PMID38444675
PMCPMC10912171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.